The second-generation ErbB family blocker, afatinib, is approved for the first-line treatment of <i>EGFR</i> mutation-positive NSCLC and has been shown to have a broad inhibitory profile against common and uncommon <i>EGFR</i> mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.